Testing mini-CHOP versus adding polatuzumab for lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study compares two lymphoma treatments: mini-CHOP alone versus mini-CHOP plus a drug called polatuzumab vedotin. It aims to see which regimen works better and is tolerable for older or frail people with certain types of aggressive B-cell lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 80+ or considered frail at 75+ by a brief aging/health check your team will do
- You have a confirmed diagnosis of one of these lymphomas: diffuse large B-cell lymphoma (including some transformed types), follicular lymphoma grade 3B, T-cell/histiocyte-rich LBCL, primary cutaneous DLBCL leg type, EBV-positive DLBCL, primary mediastinal LBCL, or high-grade B-cell lymphoma with MYC/BCL2 changes
- Your lymphoma is stage II, III, or IV, and there is at least one measurable tumor area bigger than about 1.5 cm
- You have not had any prior treatment for your lymphoma
- You are able to do study tasks (a “performance status” score of 0 to 3, depending on your situation) and can sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a “mini-CHOP-like” chemotherapy plan for newly diagnosed diffuse large B-cell lymphoma (DLBCL) in people age 70 and older. It may help you learn whether this gentler regimen works well and is safe in older adults who are newly starting treatment.
This trial tests a lower-dose combination of chemotherapy drugs (R-mini-MCOP) for people aged 80 or older who have just been diagnosed with a common type of lymphoma called DLBCL. The goal is to see if this gentler approach is effective and easier to tolerate.
This trial tests whether adding a targeted drug (X) to the standard Pola-R-CHP regimen works better for people with DLBCL whose cancer didn't respond well after the first cycle of chemo. It compares the standard treatment to a combination with an extra drug, aiming to improve outcomes for those who need it most.
This trial tests a new drug (epcoritamab) given with a milder chemotherapy combination (Pola-R-mini-CHP) for people over 70 or who are not healthy enough for standard full-dose chemotherapy. The goal is to see if this approach works as well or better with fewer side effects.
This trial tests if adding another drug (X) to a standard chemotherapy mix (Pola-RCHP) works better for people with untreated diffuse large B-cell lymphoma (DLBCL). It is for those whose cancer DNA levels did not drop enough after the first round of treatment.
This trial tests a combination of three drugs (pola, Rituxan, and lenalidomide) for older adults (70+) with a common type of lymphoma (DLBCL) who are not well enough for standard chemotherapy. The goal is to see if this gentler treatment works well for patients who are less fit.
Hear when a new DLBCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.